Tralokinumab is an IL-13 neutralizing monoclonal antibody being investigated for severe asthma. The success of neutralization of IL-5 for the treatment of severe eosinophilic asthma has increased investigation into the therapeutic potential of other type 2 cytokines, including IL-13. 3 recent trials have been conducted to assess the efficacy of tralokinumab, an IL-13 neutralizing mAb, […]
Solar Urticaria (Sun Hives)
Solar urticaria, is a type of skin response after exposure to the sun. There is an abrupt onset of redness, swelling and itching in light exposed areas. The light waves that trigger solar urticaria are usually within the range of 400 to 700 nm (visible light) and 320 to 400 nm (UV A). Patients often […]
Xolair for Food Allergies granted Breakthrough Therapy
Xolair for food allergies may become a treatment in the future as the FDA has granted Breakthrough Therapy Designation for Xolair. Xolair (omalizumab) would be used for the prevention of severe allergic reactions following accidental exposure to 1 or more foods in patients with allergies. From the FDA; Breakthrough Therapy designation is a process designed to […]
Dupilumab for Asthma, a New Indication
Dupilumab for asthma has been accepted for FDA review as an add-on maintenance treatment in adults and adolescents (12 and up) with moderate to severe persistent asthma. Dupilumab (brand name is Dupixent) is currently approved for patients with moderate to severe eczema, it was approved March 2017. Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers Dupilumab […]
Dupilumab for Nasal Polyps
Since the release of dupilumab for atopic dermatitis, studies are currently underway to investigate dupilumab for nasal polyps, asthma and a host of other conditions. Dupilumab is a human monoclonal antibody against interleukin 4 and 13. A study published in JAMA titled “Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis […]